EUVIMEDEUVIMED entdecken
VergleichsstudieRandomisierte kontrollierte StudieÄquivalenzstudieOpen Access · CC BY 4.0

Thulium fiber laser versus Holmium laser enucleation of the prostate: 24-month outcomes from a prospective randomized non-inferiority trial

Maximilian Filzmayer, Cristina Cano Garcia, Miriam I Traumann, Matthias J Müller, Clara Humke, Philipp C Mandel, Luis A Kluth, Andreas Becker, Felix K-H Chun, Marina Kosiba

World Journal of Urology · 29.04.2026 · 44 (1)

DOI: 10.1007/s00345-026-06338-9 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift World Journal of Urology, online erschienen am 29.04.2026. Verfasst von Maximilian Filzmayer und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany. filzmayer@med.uni-frankfurt.de. Hauptthemen laut MEDLINE: Lasers, Solid-State, Prostatic Hyperplasia, Thulium, Laser Therapy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johann Wolfgang Goethe-Universität, Frankfurt am Main.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To compare 24-month outcomes of Thulium fiber laser enucleation of the prostate (ThuFLEP) and Holmium laser enucleation of the prostate (HoLEP).

Methods

A 24-month follow-up analysis of a prospective randomized trial including 150 patients (ThuFLEP n = 74, HoLEP n = 76) was conducted. Primary outcome was non-inferior International Prostate Symptom Score (IPSS) and quality of life (QoL) reduction. Secondary outcomes included urinary continence, medication use reduction, erectile and ejaculatory function, and late adverse events.

Results

At 24 months, non-inferiority of ThuFLEP regarding IPSS and QoL was confirmed ( p = 0.03). Median IPSS improved from 21 preoperatively to 3 after ThuFLEP and from 20 to 4 after HoLEP ( p < 0.001), with no significant intergroup differences at any time point (all p > 0.1). Median QoL improved from 4 to 1 in both groups ( p < 0.001), likewise without significant differences at any time point (all p > 0.3). Continence rates improved from 74.0% preoperatively to 90.0%, pad usage decreased from 89.8% to 25.4% and ICIQ-SF decreased from 5 to 3 points (all p < 0.001), without intergroup differences (all p > 0.1). Use of medication for lower urinary tract symptoms decreased from 89.4% to 7.7% ( p < 0.001). Ejaculatory function declined, while ejaculation-related bother remained unchanged and erectile function improved modestly, all without intergroup differences (all p > 0.1). Three late adverse events occurred exclusively in the ThuFLEP group, without statistical significance ( p > 0.1).

Conclusion

ThuFLEP remains non-inferior to HoLEP for patient-reported functional outcomes at 24 months and demonstrates comparable safety, continence, medication use reduction, and sexual function results over time. Both techniques represent effective, durable and safe surgical options for treating benign prostatic obstruction. Trial Registration Number DRKS00032699 (18.09.2023, retrospectively registered).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lasers, Solid-StateProstatic HyperplasiaThuliumLaser TherapyProstatectomyMaleHumansProspective StudiesTreatment OutcomeTime FactorsAgedQuality of LifeFollow-Up StudiesMiddle AgedLower Urinary Tract Symptoms

Stichwörter der Autor:innen

Functional outcomesHoLEPHolmium laserLaser enucleation of the prostateLower urinary tract symptomsSoLEPSoltive™ThuFLEPThulium fiber laser

Substanzen

Thulium

Autor:innen und Institutionen

  • Department of Urology, Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany. filzmayer@med.uni-frankfurt.de.
  • Department of Urology, Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany.
  • Department of Urology, Asklepios Paulinen Clinic, Wiesbaden, Germany.
  • Urological Center at Boxberg, Neunkirchen, Germany.

Förderung

  • Johann Wolfgang Goethe-Universität, Frankfurt am Main

Zitieren

APA

Filzmayer, M., Cano Garcia, C., Traumann, M. I., Müller, M. J., Humke, C., Mandel, P. C., Kluth, L. A., Becker, A., Chun, F. K., & Kosiba, M. (2026). Thulium fiber laser versus Holmium laser enucleation of the prostate: 24-month outcomes from a prospective randomized non-inferiority trial. World Journal of Urology, 44(1). https://doi.org/10.1007/s00345-026-06338-9

Vancouver

Filzmayer M, Cano Garcia C, Traumann MI, Müller MJ, Humke C, Mandel PC, et al. Thulium fiber laser versus Holmium laser enucleation of the prostate: 24-month outcomes from a prospective randomized non-inferiority trial. World Journal of Urology. 2026;44(1). doi:10.1007/s00345-026-06338-9

BibTeX
@article{Filzmayer2026,
  author = {Filzmayer, Maximilian and Cano Garcia, Cristina and Traumann, Miriam I and Müller, Matthias J and Humke, Clara and Mandel, Philipp C and Kluth, Luis A and Becker, Andreas and Chun, Felix K-H and Kosiba, Marina},
  title = {Thulium fiber laser versus Holmium laser enucleation of the prostate: 24-month outcomes from a prospective randomized non-inferiority trial},
  journal = {World Journal of Urology},
  year = {2026},
  volume = {44},
  number = {1},
  doi = {10.1007/s00345-026-06338-9}
}
Kostenlos starten →